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ABSTRACT 
Intensity modulated radiotherapy (IMRT) is widely used in clinical applications in developed countries, for the 
treatment  of  malignant  and  non-malignant  diseases.  This  technique  uses  multiple  radiation  beams  of  non-uniform 
intensities. The beams are modulated to the required intensity maps for delivering highly conformal doses of radiation to 
the  treatment  targets,  while  sparing  the  adjacent  normal  tissue  structures.  This  treatment  technique  has  superior 
dosimetric  advantages  over  2-dimensional  (2D)  and  conventional  3-dimensional  conformal  radiotherapy  (3DCRT) 
treatments. It can potentially benefit the patient in three ways. First, by improving conformity with target dose it can 
reduce the probability of in-field recurrence. Second, by reducing irradiation of normal tissue it can minimise the degree 
of morbidity associated with treatment. Third, by facilitating escalation of dose it can improve local control. Early 
clinical results are promising, particularly in the treatment of nasopharyngeal carcinoma (NPC). However, as the IMRT 
is a sophisticated treatment involving high conformity and high precision, it has specific requirements. Therefore, tight 
tolerance levels for random and systematic errors, compared with conventional 2D and 3D treatments, must be applied 
in  all  treatment  and  pre-treatment  procedures.  For  this  reason,  a  large-scale  routine  clinical  implementation  of  the 
treatment modality demands major resources and, in some cases, is impractical. This paper will provide an overview of 
the potential advantages of the IMRT, methods of treatment delivery, and equipment currently available for facilitating 
the treatment modality. It will also discuss the limitations of the equipment and the ongoing development work to 
improve the efficiency of the equipment and the treatment techniques and procedures. © 2006 Biomedical Imaging and 
Intervention Journal. All rights reserved. 
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INTRODUCTION 
For  over  a  century,  physicists  and  clinicians  have 
been  trying  to  develop  ways  and  means  of  delivering 
doses of tumouricidal radiation, to tumours in different 
anatomical sites of patients. Various types of equipment 
and methods of treatment delivery have been developed 
to  meet  different  clinical  requirements.  Metallic  beam 
modifiers were first used in the 1960s to alter the spatial 
distribution  of  the  intensity  of  the  treatment  beams. 
These have been an effective means of providing better 
coverage of dose to the tumours. Beam blocks, wedge 
filters,  and  beam  compensators  have  been  commonly 
used  in  2-dimensional  (2D)  radiotherapy  treatments. 
Practical means of delivering intensity modulated beams 
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to achieve 3D dose conformity were not available until 
the  mid  1990s.  It  was  then  that  computer  controlled 
linear  accelerators  with  fully  motorised  multi-leaf 
collimators  (MLC)  were  developed.  In  addition,  3D 
treatment  planning  computers  with  inverse  planning 
algorithms  for  optimisation  of  dose  were  developed. 
Since  then  linear  accelerator  based  IMRT  treatment 
delivery  systems  that  include  the  binary  multi-leaf 
intensity-modulating collimator (MIMiC) [1], step-and-
shoot MLC [2], dynamic MLC (sliding window) [3] and 
intensity modulated arc therapy (IMAT) [4] have been 
developed. They are commercially available for clinical 
implementation.  Two  other  types  of  IMRT  equipment, 
with different designs, namely Cyberknife [5] and helical 
tomotherapy [6] tool have also been developed and are 
commercially available.  
Dosimetrically, IMRT has the ability to deliver the 
prescription  dose  to  the  delineated  target  volume  with 
precision,  while  sparing  the  adjacent  normal  tissue 
structures.  This  function  is  like  dose  painting  or  dose 
sculpting [7]. However, such a degree of precision and 
conformity with dose may not be realised clinically. This 
is because of uncertainties in delineating and contouring 
the target and normal tissue structures, treatment set up 
errors,  patient  and  organ  movements,  geometrical 
tolerance  of  the  treatment  machine,  and  dosimetry 
calculation errors. The purpose of this paper is to review 
the dosimetry advantages of the IMRT, clinical benefits 
that have been achieved so far, issues related to clinical 
implementation  of  the  technique,  and  limitations  of 
current equipment and clinical procedures in large scale 
implementation of the modality as a standard treatment. 
This  paper  will  also  discuss  the  research  and 
development work being conducted to resolve some of 
these problems.  
ADVANTAGES OF IMRT 
IMRT has attracted wide spread interest because of 
its dosimetric and potential clinical advantages (Figure 1). 
Numerous dosimetry studies on linear accelerator based 
IMRT treatments of different anatomical sites have been 
reported,  and  all  of  them  show  that  IMRT  can  have 
definite dosimetry advantages over 2D and conventional 
3DCRT  treatments  [8-18].  Whether  the  dosimetric 
advantages  of  IMRT  can  be  realised  clinically  would 
depend  on  a  number  of  factors,  including  (a)  the 
accuracy  in  localisation  and  delineation  of  the  tumour 
and  the  adjacent  critical  tissue  structures,  (b) 
understanding of the optimum relationship between dose 
and response for the individual tumour, and (c) delivery 
of the prescription doses according to the treatment plans. 
These are challenging requirements that need to be met. 
Some of the research and development work aiming to 
address these and related issues are discussed below.  
 
 
(a) 
 
 
(b) 
 
 
(c) 
Figure 1  A dosimetry comparison between (a) a 3-beam conventional 2D treatment, (b) a 6-beam conventional 
3D conformal RT treatment, and (c) a 7-beam IMRT treatment. The PTV is represented by the solid red 
line. The 100% and 70% of the prescription dose are shown by the green and red colour-washed areas. 
A better dose conformity to the PTV can be achieved in the IMRT treatment. 
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IMRT’s  high  conformity  with  dose  facilitates 
escalation of dose and better protection of normal tissue 
structures.  These  features  make  it  particularly  suitable 
for the treatment of diseases that involve high rates of 
local recurrence and toxicity and complications related to 
treatment. Nasopharyngeal carcinoma (NPC) is a cancer 
disease that can benefit from the treatment because of the 
recognised  radio-curability  and  the  evidence  of  a 
relationship between dose and response for the disease. 
The numerous critical normal tissue structures in close 
proximity of the tumour also warrant this treatment [8, 
19-25]. It is difficult to deliver a satisfactory radiation 
dose  distribution  to  the  NPC  target  volume  by 
conventional  radiotherapy  techniques  without 
significantly irradiating the critical tissue structures. This 
is particularly difficult in locally advanced disease [26-
27].  Planners  of  treatment  often  have  to  make 
compromises  between  protection  of  normal  organ  and 
optimal  coverage  of  dose.  IMRT  technique  has  been 
implemented routinely in our clinic since July 2000, with 
the  aim  of  improving  the  dosimetry  problem  in  NPC 
treatment.  Over  300  patients  with  early  or  advanced 
stages of NPC have been treated by means of the DMLC 
IMRT technique [8, 24]. Our early treatment outcome is 
encouraging and confirms the promising role of IMRT 
[24].  A  3-year  local  control  rate  of  92%  and  overall 
survival of 90% were achieved with a standard dose of 
66 Gy to the gross tumour volume (GTV), with limited 
acute  and  late  toxicities.  It  is  expected  that  further 
improvement  can  be  achieved  with  escalation  of  dose 
using  the  IMRT.  Escalation  of  dose  by  simultaneous 
integrated IMRT boost to a tumour dose of 76 Gy for 
treatment of locally advanced NPC has been reported by 
another centre with good short term outcome [25]. The 
2-year  local  control  and  overall  survival  reported  are 
96% and 92 %, respectively. Excellent short-term results 
have also been achieved by other centres using IMRT for 
treatment  of  NPC  [28-29],  with  high  rates  of  local 
control  of  97%  and  overall  survival  of  88%  to  97%. 
Furthermore,  the  early  clinical  data  indicate  that  the 
treatment can better spare the parotid gland, compared 
with  conventional  treatments  [22,24,30].  Encouraging 
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Figure 2  Fluence intensity map created by a pair of MLC leaf pair sliding across the radiation field. 
 
 
 
Figure 3  Typical  pattern  of  movement  of  the  MLC  leaf  pairs  when  operating  in  the  dynamic  MLC  mode 
(available for download from http://www.biij.org/2006/1/e19). 
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clinical results have also been reported on using IMRT 
for  the  treatment  of  a  number  of  other  tumour  sites, 
including  prostate,  breast,  oropharyngeal,  vulvar,  and 
anal [31-39]. While survival data are still pending, the 
main  clinical  advantages  reported  are  reduction  of 
damages to normal tissue structure caused by treatment.  
METHODS OF DELIVERING IMRT TREATMENT 
IMRT treatments are primarily delivered by linear 
accelerators  (linacs)  with  multi-leaf  collimator  (MLC) 
systems. The equipment can be commissioned to deliver 
IMRT treatment in different operation modes using MLC. 
One of the most commonly used modes of operation is 
the step-and-shoot or segmental MLC (SMLC) technique 
[2], in which, the modulation of intensity of beam in a 
treatment field is created by the exposure of a series of 
MLC  shaped  discrete  segmental  fields.  The  radiation 
beam  is  turned  off  when  the  MLC  leaves  are  moving 
from one field segment to another and is turned on only 
when the leaves reach and stop at the designated segment 
positions. The method is similar to two-dimensional dose 
painting  by the  individual segmental  fields  to  create  a 
composite  IMRT  beam  of  the  required  pattern  of 
intensity.  The  other  commonly  used  mode  of  IMRT 
delivery is the sliding window or dynamic MLC (DMLC) 
technique  [3].  The  DMLC  IMRT  beam  is  created  by 
moving  the  individual  leaf  pairs  of  the  MLC  system 
across  the  treatment  field  when  the  radiation  beam  is 
turned on. The required pattern of intensity fluence for 
the IMRT beam can be achieved by varying the width of 
the gap between each of the leaf pairs and the speed of 
travel of individual leaf pairs (Figure 2). Figure 3 shows 
a video clip of a typical pattern of movement of the MLC 
leaf pairs when operating in the dynamic MLC mode.  
The  Peacock  MIMiC  serial  tomotherapy  system 
developed by NOMOS Corporation is also a widely used 
IMRT delivery system [1]. The MIMiC multileaf system, 
which  is  a  slit  type  collimator,  is  mounted  onto  the 
treatment  head  of  a  linac  and  replaces  the  linac 
collimator  system  when  in  operation.  Dose  delivery  is 
made  through  a  narrow  slice  of  the  patient  using  arc 
rotation. Beamlets of varying intensity can be created by 
switching the individual leaves of the MIMiC multileaf 
system in and out on a binary basis. This is done when 
the radiation beam is turned on and the gantry rotates are 
around the patient. Modulation of intensity of radiation 
 
Figure 4  The dose distribution of an IMSRT treatment of a chondroma. A higher dose (shown in red colour-
washed area) can simultaneously be delivered to the main bulk of the lesion while the rest of the PTV is 
given the normal dose (shown in green colour-washed area). This is a simple form of dose painting or 
sculpting. 
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beam  is  achieved  by  varying  the  opening  time  of  the 
individual leaves during gantry rotation. On completion 
of a gantry rotation the radiation beam is switched off, 
and the patient is shifted longitudinally by moving the 
couch to treat the next adjacent axial slice. The process is 
repeated until treatment of the whole target is completed.  
The helical tomotherapy, which was developed by 
Mackie  et  al.  [6]  at  the  University  of  Wisconsin,  has 
gained popularity. The treatment unit has a mega-voltage 
linear accelerator waveguide mounted onto a computed 
tomography (CT) gantry. The gantry and couch motions 
of the machine are similar to that of a single-slice spiral 
CT. A binary MLC unit similar to that of the NOMOS 
MIMiC is used for collimation of beam and modulation 
of intensity during treatment. Modulation of intensity of 
radiation beam is achieved by varying the leaf opening 
time and gantry speed and moving the treatment couch 
like a helical CT. A set of CT detector rows is installed 
as in a conventional CT, to provide on-line mega-voltage 
CT imaging.  
A  robotic  linac,  the  Cyberknife  [5],  which  was 
developed by Accuray Inc. (Sunnyvale, CA, USA), is a 
linear  accelerator  based  high  precision  stereotactic 
radiotherapy  treatment  machine.  It  consists  of  a 
miniature linear accelerator that operates at a frequency 
about  three  times  higher  than  those  of  conventional 
linear accelerator machines. The miniature accelerator is 
mounted on an industrial robotic arm to provide a highly 
flexible 3D frameless stereotactic radiosurgery delivery 
system.  It  also  has  a  pair  of  orthogonal  on-line 
fluoroscopy  x-ray  imaging  systems  that  localise  the 
treatment  target  in  a  coordinate  system.  The  spatial 
information is then fed back to the robotic arm to direct 
the radiation beams stereotactically to the target volume 
located at the isocentre. This treatment can be considered 
as IMRT because a large number of small pencil beams 
of  different  intensities  can  be  directed  to  the  target 
volume  from  different  angles,  to  deliver  the  required 
distribution  of  dose.  The  treatments  are  delivered 
stereotactically,  with  feedback  of  any  organ  motion  to 
the robotic arm.  
Linac  based  intensity  modulated  stereotactic 
radiosurgery  (IMSRS)  or  radiotherapy  (IMSRT) 
techniques using small leaf MLC of less than 5 mm leaf 
width have been developed to improve the conformity of 
conventional  stereotactic  treatments  with  dose.  This 
technique  utilises  the  high  stability  and  high  precision 
patient immobilisation and target localisation systems of 
conventional SRT/SRS and the finer resolution of small 
leaf MLC system to further improve the conformity of 
the  treatment  with  dose,  compared  with  conventional 
IMRT  (Figures  4  and  5).  This  technique  can  better 
protect  the  critical  tissue  structures  that  are  in  close 
proximity to the treatment target. Therefore, brain, head, 
neck, and spinal cancers can be treated by utilising this 
technique [40-41].  
TREATMENT PLANNING AND SIMULATION  
The work by a number of authors [42-48] on inverse 
planning of treatment and optimisation of dose is pivotal 
to the development and the implementation of IMRT. In 
conventional  forward  treatment  planning,  the  planner 
selects  by  experience  the  required  number  of  open  or 
wedged treatment beams of appropriate beam geometries. 
The TPS calculates the composite distribution of dose by 
adding  the  dose  contributed  by  each  of  the  treatment 
beams.  If  the  dose  and  the  distribution  of  dose  are 
unsatisfactory,  the  planner  varies  the  beam  parameters 
 
Figure 5  Inter-fraction treatment set up errors (shift in isocentre) in the lateral direction of IMRT treatments 
(represented by the yellow histogram) and stereotactic treatments (represented by the blue histogram). 
Similar results are find in the superior-inferior and the anteria-posteria directions. The data confirm that 
stereotactic set up can reduce the amount of inter-fractional geometrical errors. 
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Figure 6  Principle of conventional forward planning. The planner starts with a set of beam weights and profiles to 
obtain a plan by trial-and-error process. 
 
 
 
 
Figure 7  Principle of inverse planning- The planner define the required dose & dose distribution for treatment 
and the computer can calculate and optimised the beam intensity patterns of the individual IMRT beams 
to meet the dose requirements. 
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and  geometries  and  repeats  the  calculation.  The 
processes are repeated until an acceptable treatment plan 
is achieved. In inverse planning, the planner specifies the 
required dose and the distribution of dose for the target 
volumes and the acceptable tolerance dose for individual 
normal  organs  of  interest,  in  the  form  of  a  constraint 
table for dose or template for the TPS. This is done to 
calculate the pattern of beam intensity or fluence map of 
the  individual  treatment  beams  that  are  required  to 
achieve the specified dose and the distribution of dose 
(Figure 6 and 7). The treatment planner needs to specify 
for  each  IMRT  beam  the  required  MLC  opening  that 
covers  the  target  volume,  the  gantry  and  collimator 
angles,  in  addition  to  the  dose  specification.  Upon 
satisfactory  calculation  of  the  required  map  of  beam 
intensity, the TPS can generate for each of the beams, a 
set of MLC leaf motion sequence codes. These can be 
transferred  to  the  linac  MLC  controller  to  drive  the 
individual MLC leaf movements to achieve the required 
map of beam intensity and, therefore, the dose and the 
distribution  of  dose  during  treatment.  The  degree  of 
sophistication  of  the  treatment  plan  depends  on  the 
number  of  critical  normal  organs  requiring  protection, 
the shapes of these organs, the treatment target, and the 
geometrical  margins  available  between  the  normal 
organs and treatment target. The inverse planning system 
may  not  always  be  able  to  generate  a  satisfactory 
treatment plan based on a given constraint table for dose. 
The  planner  of  treatment  may  need  to  change  the 
constraint  parameters  of  dose  and  repeat  the  iteration 
process for optimisation of dose several times before a 
satisfactory plan can be achieved. To reduce the number 
of  the  optimisation  process  and,  therefore,  minimise 
planning  time,  a  universal  or  optimised  constraint 
template of dose, for individual target sites, is required. 
This  is  very  difficult  to  achieve  in  practice  for 
complicated  treatment  sites,  such  as,  NPC  in  which  a 
large number of critical tissue structures are required to 
be protected. A TPS which can optimise the constraint 
parameters  of  dose  during  the  optimisation  process  of 
dose  needs  to  be  developed.  Another  important 
development in planning technology for treatment, which 
helps the implementation of IMRT, is the availability of 
several tools for evaluation of plans. These tools can be 
used  for  quantitative  assessment  and  comparison  of 
treatment plans. Tools for evaluation of plans, such as, 
dose-volume-histogram  (DVH)  and  dose  conformity 
index  (CI),  in  addition  to  3D  dose  and  distribution  of 
dose  analysis  tools,  are  available  in  most  planning 
systems  for  plan  evaluation.  Software  tools  based  on 
mathematical models of tumour control probability (TCP) 
and normal tissue complication probability (NTCP) are 
available to calculate these biological indices from DVH 
data. Such information can serve as useful reference for 
planners  of  treatment,  in  optimisation  of  dose  and 
evaluation of plan.  
The availability of CT simulator [49], MR simulator 
[50], and PET-CT simulator [51] facilitates accurate 3D 
localisation  and  delineation  of  target,  virtual  treatment 
simulation,  and  verification  of  radiotherapy  treatments 
for different target sites. Therefore, the geometric and the 
dosimetric accuracy of radiotherapy treatments improve 
further.  
 
Figure 8  A thermal plaster patient immobilisation cast used in IMRT treatment. 
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ISSUES IN CLINICAL IMPLEMENTATION OF IMRT  
High cost  
Clinical  implementation  of  IMRT  requires  the 
availability  of  a  range  of  sophisticated  and  high  cost 
equipment, as well as a range of compatible supporting 
facilities,  such  as,  imaging  equipment,  computer 
networks, dosimetry and quality assurance (QA) systems, 
immobilisation  system  for  patients,  and  a  multi-
disciplinary  team  of  well  trained  staff.  These  are 
expensive to establish.  
Complex and time consuming procedures  
Proper verification of dosimetry and treatment QA 
procedures  are  important  measures  to  ensure  the 
treatment  can  be  delivered  according  to  the  treatment 
plan. This is one of the limiting factors for large scale 
implementation of IMRT because of the amount of work 
involved,  physics  work  in  particular.  Early  IMRT 
techniques  for  verifying  dosimetry  were  based  on 
measurements  of  dosimetry  for  individual  patients.  A 
typical procedure for verification of treatment plan was 
to  transfer  the  treatment  plan  to  a  specially  designed 
measurement phantom [54], by replacing the patient with 
the  phantom  at  the  TPS.  Ionisation  chamber  and  film 
and/or TLD measurements were then performed with the 
phantom irradiated according to the treatment plan. The 
measured  dose  and  the  distribution  of  dose  were  then 
compared with that of the TPS calculated phantom plan 
to  verify  the  integrity  of  the  treatment.  This  type  of 
method for verifying dosimetry usually involved tedious 
and time consuming measurements of dosimetry [55-57]. 
During NPC treatment at our centre, a physicist usually 
took  about  eight  hours  to  do  a  full  verification  of 
dosimetry on an IMRT plan, with about three machine-
hours for measurement of dosimetry. This used to be one 
of  the  bottlenecks  in  the  workflow  of  our  IMRT 
programme. Therefore, the concept of virtual verification 
was developed in which the monitor unit and the fluence 
map of each of the IMRT beams as calculated by the 
TPS,  were  verified  by  means  of  an  independent  MU 
calculator  and  beam  fluence  generator  [58-59].  This 
concept works only if the treatment machines, the MLC 
leaves in particular, can operate properly and the MLC 
leaf sequence files can be transferred from the inverse 
planning  system  to  the  treatment  machines,  correctly. 
This demands that stringent QA tests be implemented to 
 
 
(a) 
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Figure 9  Stability  of  thermal plaster cast  immobilisation  system  for NPC  treatment. The  diagrams  show  the 
frequency distribution of inter-fraction treatment positioning errors due to isocentre shift in the (a) 
lateral  direction,  (b)  anterior-posterior  direction  and  (c)  superior-inferior  direction.  Frequency 
distribution of for patient immobilisation in IMRT treatment. 
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Figure 10 A PET-CT image can provide more accurate diagnostic and staging information on a lung tumour for 
IMRT treatment planning (courtesy of Dr. Hector Ma, St. Teresa’s Hospital, Hong Kong) 
 
 
Figure 11 The fusion of CT and PET provide more accurate information for IMRT treatment planning. In this 
example,  the  spread  of  lymph  mode  metastasis  of  a  nasopharyngeal  carcinoma  is  can  be  clearly 
identified (courtesy of Dr. Hector Ma, St. Teresa’s Hospital, Hong Kong) 
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test the functionality of the MLC system and the integrity 
of the network system. The idea is to replace as much as 
practicable, QA procedures that are patient specific with 
procedures that are equipment specific. Although full or 
partial verification of dosimetry may still be required to 
be  performed  on  some  of  the  plans  on  a  randomly 
sampled basis, virtual dosimetry verification can reduce 
the  patient  specific  QA  time  to  a  more  manageable 
amount.  Similar  types  of  MU  calculators  are  now 
commercially available.  
Verification  of  treatment  field  portal  is  another 
important  QA  procedure  in  IMRT.  The  procedure  is 
disease specific depending on, for example, the amount 
of  the  inter-fraction  and/or  intra-fraction  target 
movement,  although  the  objectives  are  the  same.  For 
static  treatment  targets,  the  QA  measures  are  mainly 
concerned  with  the  verification  of  the  treatment  field 
portals  by,  for  example,  comparing  the  portal  film 
images or the field portal taken by the electronic portal 
imager  (EPI)  with  the  reference  field  portals  which 
usually consist of the digital reconstructed radiographs 
(DDRs)  created  at  the  TPS  or  CT-simulator  or  the 
conventional treatment simulator images. EPIs can also 
be  used  as  dosimetry  detectors  for  on-line  electronic 
portal dosimetry (EPD) system [61-62]. This will enable 
on-line  verification  of  delivery  of  dose  in  IMRT 
treatment [63-64]. Linear accelerators with built-in EPD 
systems  are  now  commercially  available.  These  may 
help  to  improve  the  efficiency  and  the  accuracy  of 
verification of dosimetry and treatment QA procedures. 
For  mobile  targets,  the  procedures  would  be  more 
sophisticated  and  additional  measures  are  required  to 
ensure accurate localisation of the target volume. Some 
of the developments in correction of inter-fraction and 
intra-fraction target movements are discussed below. 
Patient immobilisation and target localisation 
IMRT treatments are more sensitive to geometrical 
errors,  compared  with  conventional  2D  and  3D 
treatments  because  of  their  higher  dose  conformity 
indices.  The  stability  and  the  precision  of  the  patient 
immobilisation  system  need  to  be  considered  in 
determining the amount of treatment margin required for 
proper  coverage  of  target  and  adequate  protection  of 
normal critical tissue structure. These factors about the 
system need to be maintained throughout the course of 
the  treatment.  A  well  designed  and  carefully  prepared 
thermal  plaster  immobilisation  cast  should  be 
comfortable for the patient and should be able to achieve 
an  inter-fraction  and  intra-fraction  patient  positioning 
 
Figure 12 Some of the critical normal organs of interest in NPC treatment. The PTV is contoured in red. 
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accuracy of within 3 mm throughout the course of the 
fractionated IMRT treatment (Figures 8 and 9). 
Dedicated QA programmes for equipment  
The performance of the machines used for treatment 
and the accuracy and the stability of their dosimetry and 
MLC  systems  in  delivering  the  intensity  modulated 
beams,  are  critical  in  IMRT  treatment.  This  is 
particularly  important  in  the  implementation  of  the 
virtual dosimetry verification system, which assumes the 
proper and accurate operation of the machines used for 
treatment. Dedicated and stringent QA programmes have 
been developed for equipment and reported by various 
authors. These include the design to check and ensure the 
proper operation of the machines used for treatment in 
IMRT  beam  delivery,  especially  for  checking  the 
performance and the integrity of the MLC system [54-65] 
operating in the dynamic IMRT mode.  
The need for accurate target delineation  
Accurate determination of the target volume and the 
geometry of the organs at risk (OAR) is another essential 
requirement  in  IMRT.  The  dosimetry  advantages  of 
IMRT  treatment  may  be  realised  clinically  only  if 
anatomical information on the geometries and locations 
of  the  target  volume  and  organs  at  risk  (OAR)  are 
delineated with the required precision. This information 
is essential for planning treatment and calculating dose, 
as  well  as  for  guiding  the  delivery  of  treatment.  CT 
images have the advantage of high spatial integrity and 
good  spatial  resolution.  In  addition,  they  provide 
information on electron density required for calculating 
dose of radiation. Fairly accurate delineation of the target 
and  contouring  of  the  OAR  can  be  achieved  with  CT 
images in most situations. In some situations, CT images 
alone  cannot accurately  define  the  entire  extent  of  the 
tumours  [66].  Progress  in  MRI  and  PET  imaging 
 
Figure 13 A linear accelerator with built-in kV cone beam CT system for IGRT treatment delivery (courtesy of 
Varian Medical Systems) 
 
 
       
Figure 14 CT images produced by the cone beam CT system of a linear accelerator (courtesy of Professor Lei 
Xing, Stanford University School of Medicine, USA) 
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technologies and in image registration techniques, such 
as,  multimodality  image  fusion,  has  facilitated  the 
accurate determination of the extent of gross tumour and 
the critical tissue structures of interest. CT, in the past 
two  decades,  has  played  an  important  role  in  the 
planning of radiotherapy treatment. MR images, because 
of their superior contrast resolution for soft tissues, were 
widely used for delineation of tumour in the past decade. 
The current availability of software tools for fusing MR 
and  CT  images  can  further  improve  the  accuracy  of 
contouring and delineation of soft tissue structures [67-
68].  CT  and  MRI  fused  images  have  been  found  to 
improve  the  determination  of  gross  tumour  volume 
(GTV),  clinical  target  volume  (CTV),  planning  target 
volume  (PTV),  and  organs  at  risk  (OAR)  in  NPC 
planning [69]. Functional MRI is another useful tool that 
can provide information on the activities and functional 
map of the brain, which in turn allows better delineation 
of the brain tumours and the sensitive functional regions 
of the brain [70]. The inadequacy of CT in delineation of 
tumour volume can in most cases be partially overcome 
by MR imaging. Positron emission tomography (PET) is 
another imaging modality that can enhance the accuracy 
of  localisation  of  target  and  contouring  for  planning 
IMRT treatment. Studies by Grosu et al. [71] in patients 
with  brain  tumours  have  shown  that,  compared  to  CT 
and  MRI  alone,  the  image  fusion  of  CT  or  MRI  and 
amino  acid  SPECT  or  PET  enables  a  more  correct 
delineation of GTV and PTV. The use of F-18 labeled 
fluorodeoxyglucose  positron  emission  tomography 
(FDG-PET)  imaging  has  been  found  to  improve 
significantly  the  diagnosis  and  the  staging  of  cancers, 
such as, lung cancers, compared with CT alone [72-73] 
that helps to improve accuracy in delineation of target 
volume (Figure 10). The availability of integrated PET-
CT can further improve the accuracy of diagnosis and 
staging  of  cancer  disease  [74].  A  potential  benefit  of 
PET-CT  based  planning  is  its  ability  to  exclude  or 
include  CT  suspicious  lymph  nodes  from  the  target 
volume  [51]  (Figure  11).  While  FDG-PET  has  been 
found useful in defining the nodal extension for planning 
lung treatment, the usefulness of the current equipment 
in  improving  the  accuracy  of  delineation  of  highly 
inhomogeneous moving target, such as, lung tumour, is 
still to be investigated. This is because of issues, such as, 
uncertainties in defining the tumour edge in PET scans, 
limitation  in  spatial  resolution,  and  motion  of  tumour 
[75].  
Unresolved problems in organ contouring  
Contouring of targets of treatment and OARs is a 
tedious and time consuming process in IMRT because of 
the large number of CT images involved and the level of 
precision required. The problem is more serious in head 
and  neck  cancers,  such  as,  NPC  that  requires  the 
contouring of more then 30 structures on as much as 100 
CT slices, typically, 2.5 mm thick (Figure 12). It usually 
takes an experienced radiation oncologist about one hour 
to contour the targets of treatment and a further one to 
two  hours  to  contour  all  the  relevant  critical  normal 
tissue  structures.  The  current  generation  of  automatic 
segmentation  software  tools  is  not  very  helpful  in 
contouring  some  of  the  critical  normal  soft  tissue 
structures  that  do  not  have  sufficient  CT  number 
differentiations at the boundaries. One option to reduce 
the contouring time is to use less CT images by using 
thicker  CT  slices  of  5  mm  instead  of  2.5  mm.  This, 
however,  can  introduce  significant  dosimetry  errors  in 
some of the serial organs, such as, brain stem and optic 
nerves  in  NPC  treatment  plans,  especially  in  locally 
advanced  disease.  Until  more  efficient  and  accurate 
 
Figure 15 A tomotherapy unit (courtesy of Hong Kong Sanatorium & Hospital, Hong Kong) 
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segmentation software tools are available, delineation of 
target and organ remains to be one of the limiting factors 
in large scale implementation of IMRT.  
Management of interfraction target movements  
The  day-to-day  positional  changes  in  the  target 
volumes  of  some  cancers  such  as  prostate,  cervix, 
bladder, and rectum, can be a limiting factor in IMRT 
treatment. This is particularly true for escalation of dose, 
which is more sensitive to uncertainty in treatment than 
conventional  2D  and  3DCRT  treatments  [76-77]. 
Interfraction organ motion of this sort, which can cause 
significant dosimetric deficiencies in the target volumes, 
is commonly accounted for by using appropriate margins 
when  contouring  the  PTV  [78].  For  highly  conformal 
treatments, such as, IMRT, the required margins can be 
relatively quite large [78-79], and is a trade off for the 
type of treatment. Correction techniques using in-room 
ultrasound  or  CT-guided  adjustment  of  positions  for 
treatment  before  delivery  of  treatment  have  been 
developed to minimise the effects of interfraction organ 
movements [77,80]. Adaptive treatment techniques have 
also been developed aiming to account for interfraction 
organ movement in high precision radiotherapy [81-82]. 
In  this  technique,  a  continuous  adaptation  of  the 
treatment  plan  was  made,  based  on  anatomical 
information  obtained  through  daily  CT  images  of  the 
movement of the PTV over time. The technique aims to 
optimise the coverage of target and minimise the amount 
of irradiation of normal tissue. Adaptive technique using 
an in-room integrated CT-linear accelerator has also been 
developed [83].  
Inter-fraction  target  position  changes  and  set  up 
errors  can  be  minimised  by  using  the  image-guided 
radiotherapy (IGRT) technique. Linear accelerator based 
IGRT system with add-on or integrated cone beam CT 
imaging  facilities  with  x-ray  operating  at  kV  or  MV 
energy have been or are being developed for verification 
and  correction  of  beam  geometry.  The  cone  beam  CT 
system  can  produce  high  quality  CT  images  that  can 
enable  target  matching  and  correction  of  position 
immediately before treatment (Figures 13 and 14). The 
Helical  tomotherapy  system  (TomoTherapy  Inc.,  WI, 
USA) provides helical CT image guided IMRT treatment 
without  changing  the  patient’s  position  throughout  the 
treatment and the imaging processes. The mega-voltage 
CT imaging system can produce good quality CT images 
for  verification  of  target  position  prior  to  treatment 
(Figures 15 and 16). 
 
Figure 16 On-line treatment verification by matching of the planning CT image (bottom left) with the tomotherapy 
treatment set up image (top left) immediately before treatment delivery without moving the patient 
(courtesy of Hong Kong Sanatorium & Hospital) 
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Management of intrafraction target movements  
One of the major challenges in treating tumours in 
the  cardio-thoracic  region,  as  in  the  case  of  lung, 
pancreas,  or  liver  cancers,  is  the  respiratory  induced 
movement of target during treatment. Figure 17 shows a 
video clip of lung tumour movements in one respiratory 
cycle. The respiratory motion of the lung can displace 
the target tumour away from the treatment field portal, 
resulting in inadequate coverage of dose for the tumour. 
To  ensure  satisfactory  coverage  of  dose  for  the  target 
volume, a large margin in excess of 2 cm was required to 
be  added  to  the  clinical  target  volume  (CTV)  in  lung 
treatment  [84-85].  This  resulted  in  a  larger  volume  of 
normal  lung  tissues  to  be  irradiated,  which  in  turn, 
increased the probability of morbidity and limit the dose 
that can be safely given. Such intra-fractional movement 
of  target  is  often  a  limiting  factor  for  dose  in  IMRT 
treatment  and,  particularly,  escalation  of  dose.  The 
current generation of cone beam and helical CT imaging 
systems  cannot  be  used  readily  for  correcting 
geometrical  errors  due  to  movement  of  patient  and 
motion  of  organ  during  treatment.  Specially  designed 
respiratory control equipment that can be used to limit or 
compensate for motions of organ, is now commercially 
available. One such equipment is the stereotactic body 
frame  developed  by  Elekta  AB  (Sweden)  [86].  The 
system restrains the breathing volume of the patient and, 
therefore,  limits  the  movement  of  the  target  during 
treatment.  The  active  breathing  control  (ABC)  system 
developed by Wong et al. [87] is another system that can 
be used to control and hold the patient’s breathing so as 
to  immobilise  the  target  of  treatment  for  irradiation. 
Another motion compensation system, which is currently 
in  clinical  use  in  our  hospital,  is  the  RPM  respiratory 
gating system developed by Varian Medical Systems, Inc. 
The system operates in conjunction with a diagnostic 4D 
CT scanner that is used to acquire a set of respiratory 
gated CT images, and at the same time the corresponding 
waveform  motion  of  an  infrared  marker  on  the  chest 
surface,  as  detected  by  a  camera  (RPM  waveform),  is 
recorded. The organ’s motion as shown by the 4D CT 
images is then correlated with the RPM waveform that 
can be used for compensation of motion during treatment 
(Figure 18). These two types of compensation systems 
for respiratory motion have several limitations. They are 
 
Figure 17 Video  clip  on  a  lung  tumour  movement  during  a  respiratory  cycle  (available  for  download  from 
http://www.biij.org/2006/1/e19). 
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Figure 18 Gating  of  radiotherapy  treatment  beams  by  respiratory  motion  waveform  to  compensate  for  target 
movement. 
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unsuitable for treating patients who are not cooperative 
and patients who have unsatisfactory physical conditions. 
The  exact  location  of  the  target  of  treatment  and  the 
dynamics of its motion on the day of treatment cannot be 
verified accurately unless a CT scanner is available in the 
treatment room.  
Another compensation method for motion of organ 
is the IGRT technique. It is based on a bi-plane x-ray 
fluoroscopy target localisation and tracking system, such 
as,  the  Exac-Trac  X-ray  (BrainLAB  AG,  Germany) 
imaging system (Figure 19). As shown in the video clip, 
the  orthogonal  bi-plane  x-ray  fluoroscopy  imaging 
system  localises  the  target  and  tracks  its  movement 
during  treatment.  The  radiotherapy  treatment  beam  is 
turned-on  when  the  target  enters  the  range  of  field 
coverage of the treatment beam and is turned-off when 
the target is outside the field coverage. The x-ray target 
tracking system can localise the target volume accurately 
and  provide  information  on  the  dynamics  of  its 
movement. This can be used to guide the treatment.  
Radiation safety  
As  compared  with  conventional  treatments  IMRT 
treatments, in general, require the use of more machine 
monitor units (MU) per target dose. In the case of NPC 
treatments using the sliding window technique, a factor 
of  5  or  more  MU  is  used  in  IMRT,  compared  with 
conventional  2D  or  3D  treatments.  This,  in  turn,  will 
cause a higher integral dose to be delivered to the normal 
tissues of the patient, in addition to the fact that IMRT 
generally used more radiation beams. This can result in 
an increased risk of malignancies induced by secondary 
radiation  [88-89].  The  radiosensitivity  of  the  normal 
tissues can also be enhanced, increasing normal cell-kill. 
This, in turn, can contribute to late toxicity and reduced 
therapeutic ratio [90]. As a much larger number of MUs 
are used on each patient undergoing IMRT, the adequacy 
of  the  room  shielding  should  also  be  assessed  for 
radiation safety prior to implementation of the treatment 
modality. The corresponding increase in head leakage of 
treatment  machine  and  scatter  radiation  must  be  taken 
into consideration for secondary shielding, which would 
depend on the patient load in IMRT [91]. For the same 
reason,  IMRT  treatments  using  high  energy  photon 
beams, above 10 MV, can have more serious problems of 
neutron activation. The ambient background radiation in 
the  treatment  room  can  be  significantly  elevated 
following  the  treatments  and  thus  causing  higher  staff 
dose.  
FUTURE DEVELOPMENTS AND APPLICATIONS 
Image registration and segmentation tools 
A major bottle-neck in the IMRT work flow in a 
busy centre is the registration of image and contouring of 
organ. The current generation of image registration and 
contouring  software  is  slow  and  tedious.  Better 
segmentation  tools  are  needed  for  large  scale 
implementation of IMRT in such centres.  
Biological imaging guided radiotherapy 
IMRT has the capability to paint or sculpt the dose 
of  radiation  to  conform  to  the  geometries  of  different 
 
Figure 19 Video clip on principle of the BrainLab Exac-Tract X-ray treatment (courtesy of BrainLab, Germany) 
(available for download from http://www.biij.org/2006/1/e19). 
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sub-targets within a PTV. The current limitation is in the 
ability  of  the  planners  to  delineate  such  sub-targets 
accurately. The advancement in imaging technology and 
technique  can  help  to  characterise  the  tumours  and 
delineate  the  volumes  of  iso-sensitivity  to  dose. 
Functional  imaging  techniques,  such  as,  MR 
spectroscopy, SPECT,  and  PET  can  provide  metabolic 
and  functional  imaging  of  hypoxia,  cell  proliferation, 
apoptosis,  tumour  angiogenesis,  and  gene  expression. 
This can enable identification of differently aggressive 
areas of a biologically inhomogeneous tumour mass that 
can be individually targeted using IMRT. Therefore, a 
biological,  inhomogeneous  distribution  of  dose  can  be 
generated, the so-called dose painting or dose sculpting 
within the PTV, so as to improve the therapeutic ratio of 
the treatment [7, 71]. Feasibility study of this technique 
should be carried out.  
IGRT for compensation of motion or tracking of target  
Various methods of IGRT are being developed to 
manage  or  compensate  for  movements  of  organ  and 
errors  in  the  positioning  of  patient.  Progress  has  been 
made  in  correcting  inter-fraction  positional  changes  of 
organ  between  treatment  sessions.  A  good  solution  to 
compensate  for  intra-fraction  movements  of  target, 
without having a long treatment delivering time has yet 
to  be  developed.  The  current  methods  for  tracking  of 
target and gated radiotherapy are complex and inefficient. 
While  they  may  be  applicable  for  guiding  3DCRT 
treatments,  they  are  impractical  for  implementation  in 
IMRT treatment. Further research is required before the 
technique can be applied in IMRT.  
Automation in treatment and dosimetry QA procedures 
Automation in positioning of patient and in set up 
based  on  internal  and  external  marker  tracking  is 
available for accurate and efficient delivery of treatment. 
EPI with solid state flat panel detectors are becoming a 
matured  technology  for  routing  implementation  of  on-
line  verification  of  field  geometry.  Although  on-line 
electronic  port  dosimetry  system  is  becoming 
commercially available, practical, efficient, and reliable 
automated on-line treatment dosimetry QA is yet to be 
developed. This technology can help to simplify some of 
the  QA  procedures  and  facilitate  large  scale  clinical 
implementation  of  IMRT  and  other  high  precision 
treatments.  
Clinical applications and studies  
There is, in general, a lack of published data on the 
results  of  randomised  clinical  studies  to  prove  the 
efficacy of IMRT. This is partly because the treatment 
modality is still relatively young, and meaningful long 
term clinical follow up data have yet to be collected and 
analysed.  Another  possible  reason  for  this  may  be  the 
lack of drive in the radiotherapy community to conduct 
randomised trials. The lack of drive could be because of 
the  obvious  dosimetric  advantages  of  IMRT  over 
conventional  treatments  and  the  encouraging  early 
clinical results of the treatment. However, it is expected 
that clinical results of randomised trials will be available 
in the coming years, including those of NPC trials that 
are being conducted in Hong Kong.  
It has been shown in a recent retrospective study on 
the pattern of local failure in a group on non-metastatic 
NPC patients [95] that improvement in target localisation 
or dose conformity alone, without dose escalation, can 
only  avoid  less  than  20%  of  the  local  failure  that  is 
attributable  to  radiographic  miss  or  sub-optimal  target 
coverage.  Within-field  failure  was  found  to  be  the 
predominant mode of local failure, which indicated that 
there was a relationship between dose and response in 
NPC patients. In addition, the strategy to escalate dose, 
used to increase the physical dose to the tumour bed in 
NPC  of  advanced  T-stages  appears  to  have  clinical 
benefits  [22,24-25].  These  observations  may  form  the 
basis for randomised studies to be carried out to address 
the issue of optimal dose in NPC treatment using IMRT. 
Optimisation of dose distribution within the PTV, taking 
into consideration characteristics of the tumour cells in 
different  parts  of  the  PTV  (e.g.  tumour  burden, 
proliferation, and hypoxia) in NPC treatment, should be 
investigated. 
Emerging data have indicated that there is a dose-
response for non-small cell lung carcinoma. [92-94]. It 
may  be  a  potential  treatment  site  for  dose  escalated 
treatment  using  IMRT.  The  maturing  technology  of 
4DCT,  respiratory  gated  target  motion  compensation, 
and immobilisation of target by breathing control during 
treatment, facilitate safe delivery of a highly conformal 
escalated dose of radiation to the target. Improvement in 
planning  computer  dosimetry  algorithm  can  further 
improve the accuracy and conformity of delivering dose 
to  the  target,  in  the  lung.  Research  and  development 
work on image guided on-line real time target tracking 
treatment compensation systems is being conducted. If 
this materialises, the problem of intra-fraction motion of 
organ can be resolved and the therapeutic ratio of lung 
treatment can be improved. 
CONCLUSION 
IMRT has shown to have dosimetry advantages over 
conventional 2D and 3DCRT treatment techniques in a 
number  of  cancer  sites.  Clinical  data  are  beginning  to 
show that the treatment is safe and effective. It appears 
that IMRT is more beneficial for: a) disease sites that 
have  recognised  radiocurability  and  evidence  of  a 
relationship between dose and response for the escalation 
of  dose;  and  b)  the  numerous  critical  normal  tissue 
structures in close proximity to the tumour that preclude 
the use of other treatment techniques. The technique has 
shown  to  have  survival  and  other  clinical  benefits  in 
treatment  of  NPC,  compared  with  conventional  2D 
treatments,  and  a  large  scale  implementation  of  the 
technique for treatment of this disease appears to be fully 
justifiable. While survival benefit remains to be seen, the 
technique has benefited treatment of prostate cancer by 
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reducing  complications  related  to  treatment,  compared 
with  conventional  2D  treatment.  This  suggests  that 
replacing  2D  treatment  with  IMRT  can  be  justified. 
Clinical data reported on a number of other disease sites 
also  demonstrated  similar  benefits  in  the  reduction  of 
complications  related  to  treatment  It  is  expected  that 
more sites of treatment will be found to have benefited 
from the treatment when more clinical data are available. 
However, due to limitations of current equipment, it is 
not expected that all the dosimetry benefits of IMRT will 
be fully realised clinically in the near future. Perhaps, not 
until  practical  solutions  for  accurate  and  correct 
delineation of the target volumes, proper compensation 
for  motions  of  organ  during  treatment,  and  change  in 
position of these structures with time can be found and 
corrective  measures  be  clinically  implemented.  The 
research  and  development  work  being  conducted  by 
academic institutions and manufacturing industries and 
the  exciting  progress  being  made  in  the  areas  of 
biological  imaging,  dosimetry  techniques,  and  image 
guided  IMRT  look  promising  for  improving  the 
efficiency  and  effectiveness  of  the  technique.  The 
modality  of  treatment  is  expected  to  have  a  positive 
impact  on  the  clinical  outcome,  especially  in  locally 
advanced cancer diseases. This impact will be in terms of 
reduction  of  complications  related  to  treatment  and 
increase in overall survival rates when these technology 
become more matured and IMRT is more widely used as 
standard treatment in clinics. 
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